共 50 条
- [32] MEDI4736, an anti-PD-L1 antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2013, 49 : S161 - S161Khleif, S.Lutzky, J.Segal, N.Antonia, S.Blake-Haskins, A.Stewart, R.Robbins, P.Shalabi, A.Ibrahim, R.Wolchok, J.
- [33] Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancerCANCER RESEARCH, 2015, 75Reid, TonyFisher, GeorgeCarter, CoreyCho-Phan, CherylKunz, PamelaOronsky, BryanFanger, Gary R.Caroen, ScottParker, ChristopherScicinski, Jan
- [34] PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY RESULTS FROM A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR CIN-107JOURNAL OF HYPERTENSION, 2023, 41 : E42 - E43Freeman, Mason W.Bond, MaryMurphy, BrianHui, JamesIsaacson, Jonathan
- [35] ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson's Disease: Results from A Phase I/II Clinical StudyNEUROLOGY, 2019, 92 (15)Davis, RobertRiesenberg, RobertLaskowitz, DanielGuptill, JeffSanders, LaurieCooney, JeffreySatlin, AndrewO'Brien, JenniferDuthiel, SophieCruz, StephanieHendrick, JosephLi, PengWennogle, LawrenceGlass, StevenPinho, MariaTaylor, EveKozauer, SusanWeingart, MichalMates, SharonSnyder, GretchenVanover, Kimberly
- [36] Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)BLOOD, 2017, 130DeAngelo, Daniel J.Quiery, Albert ThomasRadia, DeeptiDrummond, Mark W.Gotlib, JasonRobinson, William A.Hexner, ElizabethVerstovsek, SrdanShi, HongliangAlvarez-Diez, TerriSchmidt-Kittler, OlegEvans, EricaHealy, Mary EllenWolf, Beni B.Deininger, Michael W.
- [37] Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma CellsBLOOD, 2019, 134Ng, Patrick P.Mobasher, MehrdadYeung, Kitman S.Hotson, Andrew N.Hill, Craig M.Madriaga, AntonettDao-Pick, Trang P.Verner, ErikRadeski, DejanKhodadoust, Michael S.Kim, Youn H.Miller, Richard A.Buggy, Joseph J.Janc, James W.
- [38] PHARMACOKINETICS, SAFETY AND TOLERANCE OF BCD-085, A NOVEL IL-17 INHIBITOR, BASED ON THE RESULTS OF PHASE 1 CLINICAL STUDY IN HEALTHY VOLUNTEERSANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 429 - 429Chernyaeva, E.Eremeeva, A.Galustyan, A.Ivanov, R.
- [39] Exploration of GLPG0634, the First Selective JAK1 Inhibitor, in Inflammatory Bowel Disease Is Supported by Early Clinical Results and Mouse DSS-Colitis DataGASTROENTEROLOGY, 2014, 146 (05) : S49 - S49Galien, ReneMerciris, DidierVanhoutte, Frederic P.Delachaume, CaroleNamour, Florence S.Vayssiere, BeatriceVan der Aa, AnnegretBrys, Reginaldvan't Klooster, Gerben A.
- [40] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN StudyBLOOD, 2022, 140Wierda, William G.Lewis, David JohnGhia, PaoloShah, Nirav N.Coombs, Catherine C.Cheah, Chan Y.Lamanna, NicoleRhodes, Joanna M.Hoffmann, MarcMa, ShuoEyre, Toby A.Munir, TalhaPatel, Manish R.Alencar, Alvaro J.Tam, Constantine S.Seymour, John F.Jurczak, WojciechLech-Maranda, EwaRoeker, Lindsey E.Thompson, Philip A.Abada, Paolo B.Wang, ChunxiaoNair, BinojLiu, HuiTsai, Donald E.Mato, Anthony R.